GLPG GALAPAGOS NV

Nasdaq glpg.com


$ 31.32 nm (nm)    

Friday, 14-Nov-2025 15:50:13 EST
QQQ $ 608.75 nm (nm)
DIA $ 471.98 $ -2.94 (-0.62 %)
SPY $ 671.90 nm (nm)
TLT $ 88.93 nm (nm)
GLD $ 375.91 nm (nm)
$ 31.49
$ 31.28
$ 31.31 x 2
$ 31.32 x 2
$ 31.13 - $ 31.82
$ 22.36 - $ 37.78
173,924
na
2.08B
$ 0.60
$ 13.82
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 rbc-capital-maintains-sector-perform-on-galapagos-raises-price-target-to-32

RBC Capital analyst Brian Abrahams maintains Galapagos (NASDAQ:GLPG) with a Sector Perform and raises the price target from ...

 galapagos-nv-to-present-new-in-vitro-pharmacological-data-on-its-selective-tyk2-inhibitor-glpg3667-at-acr-convergence-2025-conference-in-chicago-from-october-2429-2025

Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that it will present new in vitro pharmacological data from its sel...

 rbc-capital-maintains-sector-perform-on-galapagos-raises-price-target-to-28

RBC Capital analyst Brian Abrahams maintains Galapagos (NASDAQ:GLPG) with a Sector Perform and raises the price target from ...

 leerink-partners-upgrades-galapagos-to-outperform-raises-price-target-to-40

Leerink Partners analyst Faisal Khurshid upgrades Galapagos (NASDAQ:GLPG) from Market Perform to Outperform and raises the p...

 galapagos-plans-to-wind-down-cell-therapy-business-and-redirect-cash-toward-transformational-deals

Intention follows comprehensive strategic review process and would represent the optimal capital allocation pathway to support ...

 galapagos-nv-advances-cell-therapy-business-divestment-review-expects-decision-by-november-5-2025

Mechelen, Belgium; October 1, 2025, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) and its Board of Directors today iss...

 galapagos-q2-eps-145-misses-009-estimate-sales-86330m-beat-71332m-estimate

Galapagos (NASDAQ:GLPG) reported quarterly losses of $(1.45) per share which missed the analyst consensus estimate of $(0.09) b...

 galapagos-reports-97-complete-response-rate-with-glpg5101-in-phase-12-atalanta-1-trial-for-relapsedrefractory-inhl

Of the 34 patients enrolled in Cohort 3 of the ATALANTA-1 Phase 1/2 study, 32 received GLPG5101; 94% were infused with fresh CA...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION